Gender differences in the endotoxin-induced inflammatory and vascular responses: Potential role of poly(ADP-ribose) polymerase activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 315, Issue 2, 2005, Pages 812-820

  Mabley, Jon G ^a,b   Horváth, Eszter M ^a,c   Murthy, Kanneganti G K ^a   Zsengellér, Zsuzsanna ^a   Vaslin, Anne ^a   Benko, Rita ^a,c   Kollai, Márk ^c   Szabó, Csaba ^a,c,d  

^a INOTEK CORPORATION   (United States)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^d University of Medicine and Dentistry of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENDOTOXIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; INO 1001; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXIDIZING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA STRAND BREAKAGE; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN ACTIVITY; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; LIVER INJURY; MALE; MEDIATOR RELEASE; MOLECULAR RECOGNITION; MORTALITY; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN DNA BINDING; SERUM; SEX DIFFERENCE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANGIOTENSIN II; ANIMALS; BLOOD VESSELS; CELL LINE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENDOTOXINS; ENZYME ACTIVATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; GLUCOSE; INFLAMMATION; MACROPHAGES; MALE; MICE; OVARIECTOMY; POLY(ADP-RIBOSE) POLYMERASES; SEX CHARACTERISTICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27144555760     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.090480     Document Type: Article

References (25)

1. Angele MK, Schwacha MG, Ayala A, and Chaudry IH (2000) Effect of gender and sex hormones on immune responses following shock. Shock 14:81-90.
2. Barkhem T, Nilsson S, and Gustafsson JA (2004) Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics 4:19-28.
3. Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC, Graham SH, and Clark RS (2004) Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 279:38563-38570.
4. Garcia Soriano F, Virag L, Jagtap P, Szabo E, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, et al. (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108-113.
5. Gavaler JS (2002) Oral hormone replacement therapy: factors that influence the estradiol concentrations achieved in a multiracial study population. J Clin Pharmacol 42:137-144.
6. Greenspan FS and Gardner DG (2003) Basic and Clinical Endocrinology, McGraw-Hill, New York, NY.
7. Graziani G and Szabó C (2005) Clinical applications of PARP inhibitors. Pharmacol Res 52:109-118.
8. Harris PE, Bouloux PM, Biller BMK, and Bouloux H (2002) Endocrinology in Clinical Practice, Martin Dunitz, London, UK.
9. Ha HC and Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96:13978-13982.
10. Hagberg H, Wilson MA, Matsushita H, Zhu C, Lange M, Gustavsson M, Poitras MF, Dawson TM, Dawson VL, Northington F, et al. (2004) PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90:1068-1075.
11. Jagtap P, Soriano FG, Virag L, Liaudet L, Mabley J, Szabo E, Hasko G, Marton A, Lorigados CB, Gallyas F Jr, et al. (2002) Novel phenanthridinone inhibitors of poly (adenosine 5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 30:1071-1082.
12. Jagtap P and Szabó C (2005) Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4:421-440.
13. Jagtap PG, Baloglu E, Southan GJ, Mabley JG, Li H, Zhou J, van Duzer J, Salzman AL, and Szabó C (2005) Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem 48:5100-5103.
14. Leal AM, Begona Ruiz-Larrea M, Martinez R, and Lacort M (1998) Cytoprotective actions of estrogens against tert-butyl hydroperoxide-induced toxicity in hepatocytes. Biochem Pharmacol 56:1463-1469.
15. Liaudet L, Soriano FG, Szabo E, Virag L, Mabley JG, Salzman AL, and Szabó C (2000) Protection against hemorrhagic shock in mice genetically deficient in poly-(ADP-ribose) polymerase. Proc Natl Acad Sci USA 97:10203-10208.
16. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, and Hurn PD (2005) Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 25:502-512.
17. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, and Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. J Am Med Assoc 288:872-881.
18. Prokai L, Prokai-Tatrai K, Perjesi P, Zharikova AD, Perez EJ, Liu R, and Simpkins JW (2003) Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci USA 100:11741-11746.
19. Rosano GM and Panina G (1999) Oestrogens and the heart. Therapie 54:381-385.
20. Schroder J, Kahlke V, Staubach KH, Zabel P, and Stuber F (1998) Gender differences in human sepsis. Arch Surg 133:1200-1205.
21. Szabó C, Pacher P, Zsengellér Z, Vaslin A, Komjáti K, Benkö R, Mabley JG, Min C, and Kollai M (2004) Angiotensin II mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 10:28-35.
22. Turgeon JL, McDonnell DP, Martin KA, and Wise PM (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science (Wash DC) 304:1269-1273.
23. Southan GJ and Szabó C (2003) Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10:321-340.
24. Virág L and Szabó C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54:375-429.
25. Wenger NK (2003) Menopausal hormone therapy and cardiovascular protection: state of the data 2003. J Am Med Womens Assoc 58:236-239.